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To assess Borrelia burgdorferi sensu lato (the cause of Lyme 
borreliosis) seropositivity in Germany, we tested serum 
samples from health survey (2008–2011) participants. Se-
roprevalence was 5.8% among women and 13.0% among 
men; infection risk was highest among persons >60 years of 
age. Public health interventions, including education about 
risk factors and preventive measures, are needed.
Lyme borreliosis, the most common tickborne disease in the Northern Hemisphere, is caused by infection with 
spirochetes of the Borrelia burgdorferi sensu lato (s.l.) 
complex. Five genospecies are known to be pathogenic 
for humans: B. burgdorferi sensu stricto (s.s.), B. afzelii, 
B. garinii, B. bavariensis, and B. spielmanii (1). In Europe, 
the bacterium is transmitted to humans through the bite of 
Ixodes ricinus ticks; in eastern Europe, I. persulcatus ticks 
can also transmit the bacterium.
In Europe, where the most common clinical manifes-
tation of Lyme borreliosis is erythema migrans, followed 
by Lyme neuroborreliosis and Lyme arthritis (2), data are 
sparse regarding B. burgdorferi s.l. infection rates and risk 
factors (3). Persons of all ages are at risk for infection; how-
ever, surveillance data and prospective studies in Europe 
and the United States suggest that children and the elderly 
are particularly at risk (4–6). Population-based surveillance 
data suggest that Lyme borreliosis is endemic in eastern 
Germany: annual incidence is 20–35 cases/100,000 inhab-
itants (7). Regional differences in incidence are observed, 
but data cannot be easily compared because of reporting 
biases and differences in infection awareness.
The limited representativeness and comparability of 
Lyme borreliosis surveillance data are well documented 
(8). Under such conditions, population-based serosurveys 
with high representativeness can provide valid estimates 
of the force of infection (rate at which susceptible persons 
acquire Lyme borreliosis) and the lifetime risk for infec-
tion; however, seroprevalence estimates do not necessarily 
represent cases of clinical disease. In a population-based 
seroprevalence study among 1- to 17-year-old children in 
Germany, seroprevalence increased cumulatively by age 
(9). We present data on the prevalence and determinants of 
B. burgdorferi s.l. seropositivity among adults in Germany 
during 2008–2011.
The Study
We estimated B. burgdorferi s.l. seroprevalence among 
participants of the German Health Interview and Examina-
tion Survey for Adults (DEGS). This nationwide cross-sec-
tional survey assessed the health status of 18- to 79-year-
old persons in Germany during 2008–2011 (10). The 
response rate was 48.4%; analysis of nonresponder ques-
tionnaires revealed high population representativeness. 
Data from standardized interviews were used to assess po-
tential risk factors for seropositivity. Survey weights based 
on age, sex, residence in western or eastern Germany, and 
nationality (German vs. non-German) were calculated to 
correct for deviations from the German population statis-
tics (December 31, 2010; http://www.destatis.de) and used 
throughout the analyses. The study was approved by the 
Ethical Review Board of the Medical School Charité, Ber-
lin, Germany.
As recommended for serologic confirmation of clinical 
cases, serum samples were tested for the presence of Bor-
relia burgdorferi s.l. IgG. For screening, we used an ELI-
SA based on B. afzelii extract antigen enriched with recom-
binant VlsE (an outer-surface protein) from B. burgdorferi 
s.s., B. afzelii, and B. bavariensis. ELISA-positive results 
were confirmed by line blot testing, which included purified 
antigens OspC, DbpA, and p83 from B. afzelii; recombinant 
VlsE from B. burgdorferi s.s. and B. garinii; and BmpA and 
DbpA from B. garinii, B. bavariensis, and B. spielmanii. De-
tails regarding the tests are available in the online Technical 
Appendix (http://wwwnc.cdc.gov/EID/article/21/1/14-
0009-Techapp1.pdf). All tests were performed/interpreted 
according to the manufacturer’s recommendations. To cat-
egorize samples by test results, we applied the rules shown 
in Figure 1.
We used sampling weights for all statistical analyses 
and accounted for the 2-stage sampling structure. Age-re-
lated prevalence was graphed and the values were smoothed 
by using the Lowess procedure of Stata 12.1 (StataCorp 
LP, College Station, TX, USA). We assessed differences 
between group prevalences (explanatory variables) by us-
ing the Wald test (univariable logistic regression) with 
2-sided p values. Independent risk factors for seropositivity 
were investigated by using stepwise multivariable logistic 
regression. All plausible 2-way interactions were tested.
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A total of 6,945 adults, representing 97.6% of the sur-
vey population with available blood samples, were included 
in the analysis. The overall weighted seroprevalence for B. 
burgdorferi s.l. was 9.4% (95% CI 8.4%–10.0%); serop-
revalence was significantly higher among men (13.0%) than 
women (5.8%) (p<0.01). Seroprevalence among both sexes 
increased by age (Figure 2); the increase was low among 18- 
to 50-year-old participants, most pronounced among partici-
pants >59 years of age, and higher among women than men 
>59 years of age. Seropositivity reached 20.0% (95% CI 
16.9%–23.6%) in 70- to 79-year-old participants.
Among participants >18 years of age, more than twice 
as many men than women were seropositive for B. burg-
dorferi s.l. (odds ratio 2.44, 95% CI 2.01–2.96) (Table). No 
significant interaction between sex and age was found (p 
= 0.075). Independent risk factors for seropositivity were 
residence in a rural area (p<0.001) and in southern Ger-
many (p = 0.032). Non-German citizenship was negatively 
associated (p = 0.004) with seropositivity; having a dog/cat 
in the house was not associated with a higher risk for se-
ropositivity. To facilitate comparison of our data with data 
from serosurveys lacking confirmatory testing, we have 
made our ELISA results available online (online Technical 
Appendix Table).
Conclusions
B. burgdorferi s.l. infections are common in Germany; 
Lyme borreliosis is endemic in all regions, but case num-
bers are highest in southern Germany. Previously identified 
risk factors for B. burgdorferi s.l. seropositivity in children 
(male sex and living in rural areas, small-sized towns, or 
southern Germany) were identified as risk factors for sero-
positivity among adults in our study. Holding a cat was pre-
viously shown to be a risk factor for children/adolescents 
(9), but was not a risk factor in our study. Seroprevalence 
among the oldest age group indicates that at least one fifth 
of the German population becomes infected with B. burg-
dorferi s.l. during their lifetime.
Figure 1. Categorization, according to ELISA and line blot test results, of serum samples tested for Borrelia burgdorferi sensu lato IgG, 
Germany, 2008–2011.
Figure 2. Estimated 
seroprevalence of Borrelia 
burgdorferi sensu lato IgG 
among the male and female 
population, Germany, 
2008–2011. For comparison, 
results of Dehnert et al. (9), a 
previous study among children/
adolescents <18 years of age, 
were added to the graph.
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B. burgdorferi s.l. IgG seroprevalence among blood 
donors in Italy (4.9%; n = 365) (11) and Romania (4.3%; 
n =1,598) (12) was lower than the seroprevalence in our 
study. Prevalences higher than those in our study have been 
shown in serosurveys in areas of high disease endemicity 
in southwestern Germany (16.9%; n = 1,228) (13) and Fin-
land (19.3%; n = 3,248) (14). In serosurveys of persons 
with high exposure to ticks (e.g., forestry and agricultur-
al workers), similar or higher seroprevalence rates have 
been described.
Seroprevalence rates among men in our study were 
strikingly higher than rates among women, indicating 
that tick contact/spirochete transmission is more frequent 
among men. Prospective studies in Germany and Sweden 
and surveillance data from Germany show no differences 
in clinical cases (except only a slight preponderance among 
women) that would point to substantial sex-specific differ-
ences in the development of clinical disease (5–7).
The age distribution for seropositivity reflects the pop-
ulation’s cumulative exposure to B. burgdorferi s.l.. An in-
creased risk for infection among children and persons >59 
years of age suggests that leisure activities/behaviors rather 
than occupational exposure are the main risk factor for in-
fection. Alternatively, these findings might be explained by 
a birth-cohort effect, in which the force of infection was 
lower during 1950–1990.
 
Table. Stratified seroprevalence of Borrelia burgdorferi sensu lato IgG detected by combined ELISA and line blot testing in adults and 









OR (95% CI) p value OR (95% CI) p value 
Sex        
 F 240/3,614 5.8 (4.9–6.7) Ref Ref  Ref Ref 
 M 501/3,331 13.0 (11.4–14.8) 2.44 (2.01–2.96) <0.001  2.61 (2.15–3.16) <0.001 
Age group, y        
 18–29 62/1,043 6.0 (4.5–8.0) Ref Ref  Ref Ref 
 30–39 50/829 6.3 (4.4–9.0) 1.05 (0.64–1.69) 0.854  1.07 (0.67–1.72) 0.779 
 40–49 83/1,263 6.4 (5.0–8.2) 1.07 (0.72–1.58) 0.737  1.04 (0.69–1.55) 0.856 
 50–59 126/1,373 8.5 (6.8–10.7) 1.46 (1.01–2.10) 0.043  1.39 (0.97–1.99) 0.069 
 60–69 186/1,361 13.2 (10.9–15.9) 2.37 (1.65–3.40) <0.001  2.37 (1.65–3.45) <0.001 
 70–79 234/1,076 20.0 (16.9–23.6) 3.91 (2.77–5.51) <0.001  4.02 (2.84–5.70) <0.001 
Residence location        
 West‡ 484/4,748 9.1 (8.0–10.4) Ref Ref  – – 
 East§ 257/2,197 10.4 (8.5–12.6) 1.15 (0.89–1.49) 0.273  – – 
 North¶ 181/1,767 9.0 (7.2–11.0) 1.11 (0.82–1.51) 0.479  1.16 (0.86–1.57) 0.318 
 Middle# 304/3,087 8.1 (6.7–9.8) Ref Ref  Ref Ref 
 South** 256/2,091 11.2 (9.4–13.3) 1.43 (1.08–1.88) 0.011  1.34 (1.03–1.75) 0.032 
Population of residence 
municipality 
       
 <5,000 189/1,258 15.4 (12.8–18.4) 2.50 (1.85–3.30) <0.001  2.13 (1.54–2.97) <0.001 
 5,000 to <20,000 185/1,685 10.0 (8.0–12.5) 1.51 (1.11–2.07) 0.010  1.33 (0.96–1.84) 0.082 
 20,000 to <100,000 193/2,030 8.4 (6.9–10.2) 1.24 (0.92–1.66) 0.154  1.21 (0.88–1.67) 0.231 
 >100,000 174/1,972 6.9 (5.6–8.4) Ref Ref  Ref Ref 
Foreign national††        
 No 721/6,528 10.0 (8.9–11.2) Ref Ref  Ref Ref 
 Yes 18/396 4.3 (2.5–7.5) 0.41 (0.22–0.75) 0.004  0.54 (0.30–0.90) 0.041 
Pet in household        
 None 502/4,596 9.5 (8.4–10.7) Ref Ref  – – 
 Any 217/2,182 9.3 (7.8–11.0) 0.98 (0.80–1.20) 0.834  – – 
 Dog        
  No 639/5,909 9.4 (8.4–10.6) Ref Ref  – – 
  Yes 80/858 9.3 (7.0–12.2) 0.98 (0.71–1.35) 0.909  – – 
 Cat        
  No 622/5,886 9.2 (8.2–10.3) Ref Ref  – – 
  Yes 119/1,077 10.3 (8.1–13.0) 1.13 (0.87–1.47) 0.356  – – 
 Other animals        
  No 655/ 6,001 9.7 (8.8–10.6) Ref Ref  – – 
  Yes 64/766 7.7 (5.8–10.1) 0.78 (0.56–1.07) 0.127  – – 
Total 741/6,945 9.4 (8.4–10.0) – –  – – 
*OR, odds ratio; Ref, reference; –, not included in the final model. 
†Unweighted. 
‡Western states: Baden-Württemberg, Bavaria, Bremen, Hamburg, Hesse, Lower Saxony, Northrhine-Westfalia, Rhineland-Palatinate, Saarland, 
Schleswig-Holstein. 
§Eastern states: Berlin, Brandenburg, Mecklenburg–West Pomerania, Saxony, Saxony-Anhalt, Thuringia. 
¶Northern states: Schleswig-Holstein, Hamburg, Lower Saxony, Bremen, Berlin, Brandenburg, Mecklenburg-West Pomerania. 
#Middle states: Nordrhine-Westfalia, Hesse, Saxony, Saxony-Anhalt, Thuringia. 
**Southern states: Rhineland-Palatinate, Baden-Württemberg, Bavaria, Saarland. 
††Defined as persons holding a foreign citizenship. 
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Persons living in urbanized areas had a lower prob-
ability for B. burgdorferi s.l. seropositivity, suggesting that 
exposure to infected ticks is higher in rural areas. However, 
urban populations are also at substantial risk for infection. 
Seropositivity is not equivalent to clinical disease; thus, 
seropositivity rates among the different population groups 
may not necessarily reflect the true effect of infection on 
disease burden. Furthermore, a US study showed that per-
sons can be consecutively infected by different B. burg-
dorferi strains and experience clinical manifestations with 
each infection (15).
Our seroprevalence estimates can be used, within 
the context of clinical diagnoses, to assess the likelihood 
of Lyme borreliosis in persons with test results positive 
for B. burgdorferi s.l. IgG. To reduce the incidence and 
disease burden of Lyme borreliosis, enhanced public 
health interventions are needed, including education 
campaigns targeted to parents, children, and the elderly 
about potential risk factors and preventive measures for 
Lyme borreliosis.
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